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Background: Baicalin, a flavone present in Scutellaria baicalensis Georgi, inhibits the growth of human leukemia and
myeloma cells through induction of apoptosis.
Methods: The present study was undertaken to ascertain whether cultured Burkitt lymphoma cells undergo
apoptosis when treated with baicalin. Growth rates were measured using MTT and colony formation assays, and
induction of apoptosis was quantified using Annexin V and DNA fragmentation assays. Mechanisms underlying
observed growth suppression were examined using Western blotting.
Results: Treatment of CA46 Burkitt lymphoma cells with baicalin for 48 h markedly decreased the rate of cell
proliferation; an IC50 value of 10 μM was obtained. Colony formation was almost fully suppressed at 10 μM baicalin.
CA46 cells underwent apoptosis in response to baicalin treatment as evidenced by an increase in the percentage of
cells stainable with Annexin V, by increased DNA fragmentation, and by activation of the intrinsic (mitochondrial)
pathway for cell death as characterized by increased expression of the cleaved forms of caspase-9, caspase-3, and
poly (ADP-ribose) polymerase. Additionally, baicalin was found to down-regulate anti-apoptotic and up-regulate
apoptotic components of the phosphatidylinositide-3-kinase (PI3K)/serine/threonine kinase (Akt) signaling pathway.
Conclusions: The concentrations at which baicalin altered expression of components of the PI3K/Akt pathway in
CA46 cells were comparable to those that suppressed growth and induced apoptosis, supporting the hypothesis
that the observed growth-inhibitory and apoptosis-inducing actions of baicalin in these cells are mediated by
down-regulation of this pathway.
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Burkitt lymphoma is a high-grade, rapidly-growing and
aggressive B-cell non-Hodgkin's lymphoma [1]. Three
forms are recognized: those endemic to Africa, sporadic
forms, and those associated with immunodeficiency
states. In the endemic and sporadic forms, B lympho-
cytes possess rearranged immunoglobulin genes and
most commonly carry the (8;14) chromosomal transloca-
tion of the proto-oncogene c-myc [1]. Although Burkitt* Correspondence: jdhu@medmail.com.cn
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reproduction in any medium, provided the orlymphoma is sensitive to chemotherapy, the different
regimens used to treat this cancer are associated with
varied success rates [1,2]. Prognosis depends on the
stage of the disease at diagnosis and is generally worse
for children, adolescents, and patients with co-existent
AIDS.
Baicalin is one of several pharmacologically-active fla-
vones present in Scutellaria baicalensis Georgi (Huang-
qin or Chinese skullcap), a plant widely used in
traditional Chinese herbal medicine [3]. Although baica-
lin is generally non-toxic to normal tissues, it exhibits
strong anti-inflammatory, anti-viral, and anti-tumor ac-
tivities [4,5]. Growth of human leukemia and myeloma
cells and of human hepatic, prostate, breast, lung, blad-
der, and estrogenic cancer cells is potently suppressedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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these growth-suppressive effects are thought to include
changes in oxidation/reduction status, cell cycle inhib-
ition, and induction of apoptosis [3-5]. Baicalin-
induced apoptosis in human leukemia cell lines is
mediated by production of reactive oxygen species, in-
duction of growth arrest and DNA damage-inducible
protein 153 (GADD153), decreased expression of the
anti-apoptotic protein Bcl-2, activation of the intrinsic
(mitochondrial) apoptotic pathway, DNA fragmenta-
tion, and cycle arrest at the G0/G1 boundary [6,7].
Treatment of doxorubicin-resistant human myeloid
leukemia cells with baicalin results in decreased ex-
pression of Bcl-2, c-myc, procaspase-3, and poly(ADP-
ribose) polymerase (PARP), increased expression of
Bad and cleaved PARP, and enhanced sensitivity to
doxorubicin [8]. The growth of certain types of cul-
tured lymphoma cells has been found to be suppressed
by treatment with Scutellaria baicalensis extracts con-
taining 21% baicalin [9]. However, no studies that
examine the effects of baicalin on lymphoma cell pro-
liferation have been reported.
The phosphatidylinositol-3-kinase (PI3K)/serine/threo-
nine kinase (Akt) signaling pathway is essential to the
survival and proliferation of human cells, and constitu-
tive activation of this pathway is thought to play a crit-
ical role in the progression of human hematologic
malignancies [10,11]. Inhibitors of this pathway have
been shown to induce apoptosis in isolated leukemia,
lymphoma, and myeloma cells. The CA46 lymphoma
cell line [12], which was derived from the ascites fluid of
a patient with American-type Burkitt lymphoma, carries
the (8;14) translocation, overexpresses Bcl-2 and c-myc
mRNAs, and has been proven a useful model of Burkitt
lymphoma. The following study was undertaken to as-
certain whether baicalin down-regulates the PI3K/Akt
signaling pathway in CA46 cells concurrently with in-
duction of apoptotic cell death.Materials and methods
Materials
Baicalin (C21H18O11, MW 446.35) was purchased from
Qingzhe (Nanjing, Jiangsu, China). A 50 mM stock solu-
tion was prepared by dissolving 22.3 mg of the drug in
1 ml of dimethyl sulfoxide (DMSO; Sigma, St. Louis,
MO, USA). The stock solution was maintained at −20°C
and was diluted to appropriate concentrations with cul-
ture medium immediately before experimental use.
Under these conditions, no baicalin solubility issues
were encountered. The highest final concentration of
DMSO in baicalin-treated preparations was 0.08%; the
viability of control preparations was unaffected at this
DMSO concentration.Cell culture
The Jurkat, K562, HL-60, and CA46 Burkitt lymphoma
cell lines were obtained from the China Center for Type
Culture Collection (CCTCC; Wuhan, Hubei, China).
Cultures were maintained in RPMI-1640 medium
(Gibco, Grand Island, NY, USA) with 10% fetal bovine
serum (FBS; Gibco, Grand Island, NY, USA) at 37°C in a
humidified atmosphere containing 5% CO2.
Proliferation assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium
bromide (MTT) assay was used to measure the rate of
cell proliferation. Briefly, CA46 cells (1 × 104/well) were
seeded in 96-well plates and treated with baicalin at
varying concentrations. After varying incubation times,
cells were treated with 20 μl of MTT solution (Sigma, St.
Louis, MO, USA) at a final concentration of 5 mg/ml for
4 h at 37°C. Medium was then removed, DMSO (200 μl)
was added, and the absorbance maxima at test and refer-
ence wavelengths of 490 and 630 nm, respectively, were
recorded. The proliferation inhibitory rate (%) was cal-
culated as: [1-(absorbance of baicalin treated group/
absorbance of control group)] × 100.
Colony-forming assay
CA46 cells were seeded at a density of 4 × 102/well in
24-well flat bottom plates and then cultured with baica-
lin at different concentrations in RPMI-1640 medium
with 10% FBS and 0.7% methylcellulose at 37°C for
10 days. Colony formation was observed using phase
contrast inverse microscopy. The resulting cell colonies
(>50 cells/colony) were counted, and colony formation
rate (%) was calculated as: (formed colonies/seeded
cells) × 100.
Measurements of cells in early and late apoptosis
The ability of baicalin to induce apoptosis in CA46 cells
was examined by Annexin V-FITC/PI double-staining and
flow cytometry. Preparations were treated with baicalin at
varying concentrations for 48 h. Cells were then harvested,
resuspended to 5× 105 /ml in binding buffer (HEPES,
10 mM, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2,
1.8 mM CaCl2), and doubly stained with Annexin
V-Fluorescein Isothiocyanate (FITC)/Propidium Iodide
(PI) (BD, Franklin, NJ, USA) according to the manufac-
turer’s instructions. The percentages of viable, early apop-
totic, late apoptotic, and necrotic cells were determined
using a CPICX XL flow cytometer (Beckman Coulter,
Fullerton, CA, USA).
DNA fragmentation assay
After 48 h exposure to baicalin at varying concentra-
tions, CA46 cells were collected by centrifugation and
washed twice with PBS. Cell pellets were resuspended in
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8.0, 0.8% SDS) and subsequently treated with 10 μl
RNase A (50 μg/ml) at 37°C for 1 h and with 10 μl pro-
teinase K (20 μg/ml) at 50°C overnight. Extracted cellu-
lar DNA was subjected to agarose gel (2.0%)
chromatography at 35 V for 3 h. Gels were photo-
graphed after staining with 0.5 μg/ml ethidium bromide.
Western blot analyses
Western blotting was performed as described previously
[8]. CA46 cells were treated with 40 μM baicalin for 0–72 h
prior to lysis. Protein Detector LumiGLOWestern Blot Kits
were purchased from KPL (Gaithersburg, MD, USA).
Antibodies to the following proteins were used for these
analyses: β-actin (NeoMarkers, Fremont, CA, USA); Akt,
p-Akt (Ser473), mammalian target of rapamycin (mTOR),
p-mTOR (Ser2448), IκB, p-IκB (Ser 32), PARP, cleaved
caspase-9 (Asp330), and cleaved caspase-3 (Asp175) (Cell
Signaling, Danvers, MA, USA); NF-κB p65 (eBioscience,
San Diego, CA, USA). The density of β-actin served as an
internal loading control.
Statistical analysis
Experimental findings are expressed as means ± standard
deviation. Comparisons involving different baicalin con-
centrations or incubation times were conducted using
analysis of variance (ANOVA). Multiple comparisons
were performed using the Bonferroni procedure with
type-I error adjustment when significance was obtained.
The level of significance was set at 0.05. Statistical ana-
lyses were performed using SAS 9.1 statistical software
(SAS Institute Inc., Cary, NC, USA).
Results
Inhibition of cell proliferation and colony formation
Baicalin inhibited the proliferation of CA46 cells in a
concentration- and time-dependent manner, with almost
complete inhibition observed at 48–96 h of treatment
with 20–40 μM drug (Figure 1A). An IC50 of 10 μM was
obtained (Figure 1B). After 48 h of treatment, rates of
proliferation declined in a baicalin concentration-
dependent manner, with 15.5 ± 4.7% and 89.4 ± 2.8%
inhibitions observed at 5 and 40 μM drug, respectively.
Baicalin also suppressed formation of colonies of CA46
cells at 10 days post-seeding (Figures 2A and 2B). Con-
trol preparations formed colonies at a rate of
36.2 ± 4.0%. In contrast, rates of colony formation for
preparations treated with baicalin at 5 and 10 μM were
14.0 ± 2.3% and 0.5 ± 0.5%, respectively (P <0.01).
Induction of apoptosis
The percentage of CA46 cells undergoing apoptotic cell
death was increased by baicalin in a concentration-
dependent manner (Figure 3A-D). The percentages of allcells in apoptosis, as determined by the sum of cells in
early and late apoptosis, at various baicalin concentra-
tions are presented in Figure 3E. After 48 h of treatment,
15.2 ± 1.6% of cells were apoptotic at 10 μM baicalin and
35.4 ± 2.6% of cells were apoptotic at 40 μM baicalin.
When the ability of baicalin to induce DNA fragmenta-
tion, a hallmark of apoptosis, was examined after 48 h of
culture (Figure 3F), no significant fragmentation was
observed in preparations treated with solvent or 5 μM
baicalin. However, fragmentation was clearly observable
in preparations treated with 20 and 40 μM baicalin.
Suppression of the PI3K/Akt pathway
The possibility that the induction of apoptosis in CA46
cells by baicalin involved suppression of Akt signaling
was explored. Basal expression of p-Akt (the activated
form of Akt) was examined in C46 cells, in three
leukemic cell types, and in normal peripheral blood
mononuclear cells under untreated conditions. As com-
pared to normal peripheral blood mononuclear cells,
high degrees of p-Akt expression were observed in C46
lymphoma cells and in all types of leukemic cells
(Figure 4A). The effects of baicalin on expression of
Akt and of specific downstream components of the Akt
pathway in CA46 cells were then examined. Expression of
the following components in their various forms was mea-
sured: (a) Akt (inactive) and p-Akt; (b) the transcription
factor NF-κB, the NF-κB inhibitor, IκB, and the degradable
form of IκB, p-IκB; (c) the cell cycle regulatory kinase
mTOR (inactive) and p-mTOR, the phosphorylated and
active form of the kinase. An increase in the dephosphory-
lated form of Akt was observed at 24 h of baicalin treat-
ment, and an increase in the dephosphorylated form of
mTOR was observed at 48 h of baicalin treatment. Dra-
matic reductions in expression of NF-κB and p-IκB were
observed in response to baicalin; these reductions were
time-dependent. By contrast, expression of IκB increased
with time of baicalin treatment (Figure 4B). Changes in
expression of these components were quantified, and the
findings are summarized in Figure 4C.
The profound decreases in expression of total cellular
NF-kB and p-IkB, accompanied by significant increases
in IkB expression, in response to baicalin treatment were
interpreted to indicate a condition wherein nuclear NF-
kB signaling should be dramatically impaired. Accord-
ingly, expression of nuclear NF-kB was reduced by
25.8%, 50.4% and 65.4% at 24, 48 and 72 h of treatment
with 40 μM baicalin, respectively (not shown).
Activation of the intrinsic mitochondrial apoptotic
pathway
It was considered essential to ascertain whether baicalin
suppresses proliferation of CA46 cells and promotes
DNA fragmentation in these cells through activation of
Figure 1 Proliferation of CA46 cells in the absence and presence of baicalin. Cells were seeded at a density of 1 × 104/well and treated with
baicalin at the concentrations and for the times indicated. Cytotoxicity was determined according to the MTT assay. Sampling was performed in
triplicate for each experimental condition, and findings are expressed as means ± standard deviation for three independent experiments. (A)
Proliferation as a function of incubation time and baicalin concentration. Absorbance maxima are provided on the ordinate. (B) Rates of
proliferation as a function of baicalin concentration. Cells were treated for 48 h with baicalin at the concentrations indicated. Proliferation rates
were determined as described in Materials and methods. *P <0.01 compared to the solvent control; †P <0.01 compared to 5 μM baicalin;
{P <0.01 compared to 10 μM baicalin.
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end, expression of relevant apoptosis-related proteins
was examined by Western blotting. Treatment with bai-
calin increased expression of the pro-apoptotic proteins
Bax, activated (cleaved) caspase 3, activated (cleaved)
caspase 9, and activated (cleaved) PARP. By contrast, ex-
pression of the anti-apoptotic protein Bcl-2 and of the
inactive form of PARP was decreased followingtreatment with the drug (Figure 4D). Relative expression
of these proteins after baicalin treatment was quantified,
and findings are presented in Figure 4E. The concentrations
at which baicalin altered expression of these apoptosis-
related proteins were similar to those at which cell prolif-
eration was suppressed and expression of components of
the PI3K/Akt signaling pathway was altered, supporting the
hypothesis that the growth-inhibitory and apoptosis-
Figure 2 Formation of CA46 cell colonies after treatment with baicalin at varying concentrations. Cells (4 × 102/well) were cultured with
baicalin at the indicated concentrations for 10 days. Colony formation rates were determined as described in Materials and methods. Sampling
was performed in triplicate for each experimental condition. (A), phase contrast inverse microscopy. (B), colony formation rates with findings
presented as means ± standard deviation for three independent experiments. *P <0.01 compared to the solvent control; †P <0.01 compared to
2.5 μM baicalin; {P <0.01 compared to 5 μM baicalin.
Huang et al. Journal of Experimental & Clinical Cancer Research 2012, 31:48 Page 5 of 9
http://www.jeccr.com/content/31/1/48inducing actions of baicalin in CA46 cells are mediated by
suppression of PI3K/Akt signaling pathway.Discussion
The present study is the first to demonstrate that baica-
lin is toxic to Burkitt lymphoma cells in culture. Treat-
ment with this flavone at 10 μM concentrations resulted
in a marked decrease in the rate of proliferation of cul-
tured CA46 cells and in the rate at which these cells
formed colonies. Baicalin treatment caused CA46 cells
to undergo apoptosis as evidenced by an increase in thepercentage of Annexin V-stainable cells and by increased
DNA fragmentation. Baicalin also activated the mito-
chondrial pathway for cell death, as shown by increased
expression of activated caspase-9, activated caspase-3,
and cleaved PARP. Treatment of CA46 cells with baica-
lin was found to suppress components of the PI3K/Akt
signaling pathway, as shown by decreased expression of
p-Akt, mTOR, p-mTOR, NF-κB, and p-IκB. These
decreases were observed concurrently with increased ex-
pression of non-phosphorylated IκB. The concentrations
at which baicalin altered the expression of components
of the PI3K/Akt signaling pathway were similar to those
Figure 3 Induction of apoptosis in CA46 cells by baicalin. Annexin V-FITC/PI double staining and flow cytometry were used to determine the
percentages of cells in apoptosis. Viable, early apoptotic, late apoptotic, and necrotic cells were determined after 48 h treatments with baicalin at
varying concentrations. Cells were treated with baicalin at (A) 0, (B) 10, (C) 20, and (D) 40 μM. Bottom left quadrants, viable cells; bottom right
quadrants, early apoptotic cells; top right quadrants, late apoptotic cells; top left quadrants, necrotic cells. (E) Percentages of cells in apoptosis at
each baicalin concentration. Cells in the bottom right and top right quadrants were summed to obtain the percentage of all cells in apoptosis.
Findings are presented as the means of three similar experiments ± standard deviation. (F) CA46 cells were treated for 48 h with baicalin at 0
(lane 1), 10 (lane 2), 20 (lane 3), and 40 (lane 4) μM. Cellular DNA was extracted and subjected to agarose gel electrophoresis as described in
Materials and methods. Gels were stained with ethidium bromide and photographed. Lane M presents migration of D2000-Markers (100, 250,
500, 750, 1000, 2000 bp). Findings are representative of those obtained on three separate occasions. *P <0.05 compared to the solvent control;
†P <0.05 compared to 10 μM baicalin; {P <0.05 compared to 20 μM baicalin.
Huang et al. Journal of Experimental & Clinical Cancer Research 2012, 31:48 Page 6 of 9
http://www.jeccr.com/content/31/1/48at which the drug suppressed growth and induced apop-
tosis, supporting the hypothesis that the growth-inhibitory
and apoptosis-inducing actions of baicalin in CA46 cells
are mediated by suppression of this pathway.
Although baicalin has been found to induce apoptosis
in several malignant hematologic cell types, the mechan-
ism responsible for the induction has not been examined
in detail. Baicalin treatment has been shown to promote
activation of the mitochondrial pathway of apoptosis
and to induce DNA fragmentation and cycle arrest in
human leukemia cells but the upstream mechanisms
responsible for these actions were not examined [6-8].
Baicalein, a non-glycosylated derivative of baicalin and
one of the major flavones present in Scutellaria baica-
lensis Georgi, was recently reported to induce apoptosis
in human myeloma cells through inhibition of Akt acti-
vation [13]. However, baicalein and baicalin are not iden-
tical in their cellular actions. Although both flavones
induce apoptosis in several types of murine and human
cancer cells, events mediating growth suppression by
baicalein do not routinely duplicate those mediated by
baicalin [14-19]. In addition, baicalin is unable toduplicate the baicalein-induced activation of the IL-6-
mediated signaling cascade seen in human myeloma
cells [13]. Whether baicalein is similar to baicalin in its
action on Akt and downstream mediators in Burkitt
lymphoma cells remains to be demonstrated.
The PI3K/Akt growth signaling pathway is comprised
of a family of intracellular protein kinases, each of which
is regulated by phosphorylation and possesses unique
substrate specificity. Activated Akt, the primary medi-
ator of PI3K-initiated signaling, supports survival of vari-
ous hematologic malignancies through its ability to
phosphorylate and activate a wide variety of downstream
targets [10,20,21]. In the present study, inhibition of Akt
phosphorylation, rather than down-regulation of Akt ex-
pression, was observed during treatment of CA46 cells
with baicalin. Since Akt is an early player in the PI3K/
Akt signaling pathway, it is conceivable that the growth-
suppressive effects of baicalin in CA46 cells are attribut-
able to an interaction of the drug with the kinase. In
support of this hypothesis, selective inactivation of Akt
in Jurkat T lymphoblastic leukemia cells causes these
cells to undergo apoptotic death via the mitochondrial
Figure 4 Expression of proteins associated with the PI3K/Akt signaling and the intrinsic (mitochondrial) apoptotic pathways after
varying times of treatment of CA46 cells with baicalin. (A) Expression of p-Akt in various untreated cell types as detected by phospho-Akt
specific antibody. Lane 1, CA46 cells; lane 2, Jurkat cells; lane 3, K562 cells; lane 4, HL-60 cells; lane 5, normal peripheral blood mononuclear cells-
1; lane 6, normal peripheral blood mononuclear cells-2. (B-E) CA46 cells were treated with 40 μM baicalin for the times indicated. Protein
expression was analyzed by Western blotting. (B) Western blot showing expression of β-actin, Akt, p-Akt, NF-κB, IκB, p-IκB, mTOR and p-mTOR. (C)
Expression of p-Akt/Akt, NF-κB, IκB, p-IκB, and p-mTOR/mTOR relative to that of β-actin. (D) Western blot showing expression of β-actin, Bcl-2,
Bax, cleaved caspase-9, cleaved caspase-3, and uncleaved (116 kD) and cleaved (85 kD) PARP. (E) Expression of cleaved caspase-9, cleaved
caspase-3, uncleaved and cleaved PARP, Bax, and Bcl-2 relative to that of β-actin. Findings are representative of those obtained on three separate
occasions. *P <0.05 compared to the 0 h control; †P <0.05 compared to 24 h treatment; {P <0.05 compared to 48 h treatment.
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measured in the present study, the involvement of this
kinase in the observed effects of baicalin remains un-
clear. Future studies with various lymphoma cells lines
are planned to explore the possibility that PI3K is tar-
geted by baicalin.
NF-κB and mTOR, downstream components of the
PI3K/Akt pathway, are thought to function importantly in
maintenance of hematologic malignancies [10,11,20,23-
25]. The transcription factor NF-κB is inactivated whencomplexed with IκB in the cytosol. Phosphorylation of
IκB renders it a substrate for degradation, resulting in
translocation of free NF-κB to the nucleus and tran-
scriptional activation of anti-apoptotic genes. Activated
Akt indirectly signals IκB phosphorylation, thereby pro-
moting transcription of anti-apoptotic genes, whereas in-
activation of Akt promotes apoptosis. mTOR is directly
phosphorylated by activated Akt. Phosphorylated mTOR,
the active form of the kinase, promotes cell cycle transi-
tion from the G1 to S phase via phosphorylation of its
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ation factor 4E-binding protein 1. These phosphorylations
favor translation of mRNAs for certain growth-promoting
proteins such as cyclin D and c-myc. Accordingly, pharma-
cologic antagonists of mTOR are anticipated to be effective
against many types of solid tumors and hematologic can-
cers [10,11,25]. In the present study, expression of NF-κB,
p-IκB, mTOR, and p-mTOR was found to be down-
regulated in baicalin-treated CA46 cells. These findings
support the hypothesis that induction of apoptosis in
CA46 cells by baicalin is mediated by the suppression of
PI3K/Akt/NF-κB and PI3K/Akt/mTOR signaling.
Suppression of Akt in cancer cells is associated with
activation of the mitochondrial apoptotic pathway in-
volving the caspase-9-dependent caspase cascade
[20,24]. Treatment of CA46 cells with baicalin was
found to increase the level of cleaved caspase-9 concur-
rently with a decrease in procaspase-9 protein, to in-
crease level of cleaved caspase-3 concurrently with a
decrease in procaspase-3 protein, to increase expression
of cleaved PARP concurrently with decreased expression
of uncleaved PARP, and to promote DNA degradation.
These findings support the proposal that apoptotic death
in baicalin-treated CA46 cells is mediated by the follow-
ing events in sequence: cleavage of procaspase-9, cleav-
age of procaspase-3, cleavage of PARP, and degradation
of DNA.
Based on the findings presented in this report, it is
suggested that baicalin induces apoptosis in CA46 Bur-
kitt lymphoma cells through down-regulation of the
PI3K/Akt signaling pathway and activation of the mito-
chondrial death pathway. The findings described in this
report warrant further investigations of the efficacy of
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